Nelson J. Chao, MD, MBA

Articles

Unmet Needs in GVHD Management

February 22nd 2022

Drs Sophie Paczesny, Hannah Choe, Nelson J. Chao, and Yi-Bin Chen share unmet needs in GVHD and advice for disease management.

Supportive Care for Steroid-Refractory Chronic GVHD Treatment

February 22nd 2022

Hannah Choe, MD, leads a review of the role of supportive care and a multidisciplinary team approach to care for the treatment of steroid-refractory chronic GVHD.

Clinical Manifestations of Chronic GVHD

February 22nd 2022

Drs Hannah Choe, Nelson J. Chao, Sophie Paczesny, and Yi-Bin Chen share their approach to treating patients with chronic GVHD who present initially with either scleroderma or bronchiolitis obliterans.

Future of Steroid-Refractory Chronic GVHD Treatment

February 15th 2022

Drs Hannah Choe, Yi-Bin Chen, Nelson J. Chao, and Sophie Paczesny explore emerging treatment options in the pipeline for the treatment of steroid-refractory chronic GVHD.

Treatment Selection for Steroid-Refractory GVHD

February 15th 2022

Hannah Choe, MD, leads the discussion on clinical experiences using off-label regimens to treat steroid-refractory chronic GVHD, and the optimal sequencing of therapy.

Steroid-Refractory Chronic GVHD: Management Strategies

February 8th 2022

Hannah Choe, MD; Sophie Paczesny, MD, PhD; and Nelson J. Chao, MD, MBA, review the use of current FDA approved therapies—ruxolitinib, ibrutinib, and belumosudil—for the treatment of steroid-refractory chronic GVHD.

Steroids for First-Line Treatment of Chronic GVHD

February 8th 2022

Yi-Bin Chen, MD, leads a discussion on the use of steroids as first-line treatment of chronic GVHD and when to switch therapy.

Overview of Steroid-Refractory Acute GVHD

February 1st 2022

Nelson J. Chao, MD, MBA, and Hannah Choe, MD, define steroid-refractory acute GVHD and current treatment options for the disease.

Evolution of Treatment for Acute GVHD

February 1st 2022

Sophie Paczesny, MD, PhD, provides insight on how strategies to treat acute GVHD have changed over time regarding outcomes and pathophysiology of disease.

Goals of Therapy for Acute GVHD Treatment

January 25th 2022

Hannah Choe, MD, discusses triggers to initiate acute GVHD therapy and goals of treatment.

Impact of GVHD on Patient Outcomes

January 25th 2022

Yi-Bin Chen, MD, and Nelson J. Chao, MD, MBA, comment on the changing landscape of GVHD and the effect on patient outcomes.

ASH 2021 Updates for GVHD Prophylaxis

January 18th 2022

Sophie Paczesny, MD, PhD; Yi-Bin Chen, MD; and Hannah Choe, MD, review recent advances in GVHD prophylaxis as presented at the 2021 American Society of Hematology (ASH) Annual Meeting and Symposium.

Selecting GVHD Prophylaxis

January 18th 2022

Nelson J. Chao, MD, MBA, reviews current GVHD prophylaxis options and factors to consider when selecting one for a given patient.

Challenges in Early Detection of GvHD

January 11th 2022

Hannah Choe, MD; Nelson J. Chao, MD, MBA; and Sophie Paczesny, MD, PhD, comment on the importance of early detection of disease and the role of biomarker testing in GVHD.

Overview of Graft-vs-Host Disease (GVHD)

January 11th 2022

Nelson J. Chao, MD, MBA, and Yi-Bin Chen, MD, define common signs and symptoms of GVHD and share insight on approaching the diagnosis of disease.